CSV November 24, 2022 through November 24, 2024 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FOLIC ACID	*USP Reference*	*USP41–NF36*	1866	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second*	Delete

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
INJECTION	*standards <11>*						*Supplement to USP41–NF36*	USP Endotoxin RS
ZIPRASIDONE HYDROCHLORIDE	IMPURITIES/*Organic Impurities*	*Second Supplement to USP41–NF36*	8992	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	In the second variable definition in *Analysis*: Change r_U = peak response of chloroindolinone or ziprasidone related compound F from the *Sample solution* to: r_U = peak response of chloroindolinone, ziprasidone related compound F, or any unspecified impurity from the *Sample solution*
PLASTIC MATERIALS OF CONSTRUCTION	TEST METHODS	*USP41–NF36*	6403	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Plastic Additives/Reference solutions/Reference*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution I: Change 0.24 mg/mL of USP Plastic Additive 4 RS prepared in the *Solvent mixture* to: 0.24 mg/mL of USP Plastic Additive 4 RS prepared in methylene chloride AND Line 1 of *Reference solution J*: Change 0.24 mg/mL of USP Plastic Additive 5 RS prepared in the *Solvent mixture* to: 0.24 mg/mL of USP Plastic Additive 5 RS prepared in methylene chloride

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Line 1 of *Poly(ethylene-vinyl acetate)/Polyvinyl chloride, plasticized/Reference solutions U, V, W*: Change 0.1-mg/mL solutions to: 10.0-mg/mL solutions
DIVALPROEX SODIUM DELAYED-RELEASE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP41–NF36*	1354	27-Jul-2018	1-Aug-2018	*USP43–NF38*	*Second Supplement to USP41–NF36*	Line 1 of *Tolerances*: Change NMT 20% (*Q*) of the labeled amount of to: NMT 20% of the labeled amount of
CHORIONIC GONADOTROPIN FOR INJECTION	ADDITIONAL REQUIREMENTS	*USP41–NF36*	1982	29-Jun-2018	1-Jul-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of *USP Reference Standards <11>*: Delete USP Endotoxin RS
POLYDEXTRO	ASSAY/	*First*	8491	29-Jun-2018	1-Jul-2018	*USP42–NF37*	*Second*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
SE	*Procedure*	*Supplement to USP41–NF36*					*Supplement to USP41–NF36*	*Sample solution*: Change Polydextrose, calculated on the anhydrous and ash-free basis, in *Mobile phase* to: Polydextrose in *Mobile phase* AND Line 1 of *Acceptance criteria*: Change NLT 90.0% to: NLT 90.0% on the anhydrous and ash-free basis
HYDROGENATED POLYDEXTROSE	ASSAY/ *Procedure*	*USP41–NF36*	5495	29-Jun-2018	1-Jul-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Change *Standard solution*: 4.0 mg/mL of USP Polydextrose RS, calculated on the anhydrous and ash-free basis,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								in *Mobile phase* *Sample solution*: 4.0 mg/mL of Hydrogenated Polydextrose, calculated on the anhydrous and ash-free basis, in *Mobile phase* to: *Standard solution*: 4.0 mg/mL of USP Polydextrose RS in *Mobile phase* *Sample solution*: 4.0 mg/mL of Hydrogenated Polydextrose in *Mobile phase*
NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY IDENTITY TESTING OF BACTERIAL P	2. PROCEDURE	*First Supplement to USP41–NF36*	8633	29-Jun-2018	1-Jul-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 3 of *2.1 Equipment R equ irement s/Processing Parameters*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
OLYSACCHARIDES USED IN VACCINE MANUFACTURE								Change adsorption to: absorption
CALCIUM CITRATE MALATE	IM PURITIES/*Limit of Fluoride*	*First Supplement to USP41–NF36*	8299	29-Jun-2018	1-Jul-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Standard solution*: Change Transfer 1.0 mL of *Standard stock solution* to: Transfer 2.0 mL of *Standard stock solution*
DOXEPIN HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	1404	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Doxepin Related Compound C RS: Change (*E*,*Z*)-3-(Dibenzo[*b*,*e*]oxepin-11(6*H*)-ylidene)-*N*-methyl-propoan-1-amine. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(*E*,*Z*)-3-(Dibenzo[*b*,*e*]oxepin-11(6*H*)-ylidene)-*N*-methylpropan-1-amine hydrochloride.
ETHYLENE GLYCOL AND VINYL ALCOHOL GRAFT COPOLYMER	IMPURITIES/ *Procedure 2: Vinyl Acetate*	*USP41–NF36*	5346	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 6 of *Sample solution*: Change Pass through a 0.2-mm membrane filter. to: Pass through a 0.2-?m membrane filter.
MICONAZOLE NITRATE TOPICAL POWDER	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP41–NF36*	8355	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Miconazole Related Compound C RS: Change 2-[(2,4-Dichlorobenzyl)oxy]-2-(2,4-dichlorophen

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								yl)ethan-1-amine. $C_{15}H_{13}Cl_4NO$ 365.08 to: 2-[(2,4-Dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethan-1-amine hydrochloride. $C_{15}H_{13}Cl_4NO \cdot HCl$ 401.53
CHOLESTEROL	IMPURITIES/*Limit of Related Sterols and Other Organic Impurities/Analysis*	*USP41–NF36*	5296	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	In the second variable definition list: Change C_{S2} = concentration of USP Cholesterol RS in the *Standard solution* (mg/mL) to: C_{S2} = concentration of USP Cholesterol RS in the *System suitability solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PRODUCTS FOR NEBULIZATION—CHARACTERIZATION TESTS	AERODYNAMIC ASSESSMENT OF NEBULIZED AEROSOLS	*USP41–NF36*	7874	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	(mg/mL) Line 1 of paragraph 3: Change general information chapter *Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers* <601>), to: general chapter *Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders—Performance Quality Tests* <601>),
ESZOPICLONE	ADDITIONAL REQUIREMENTS/*USP Reference Standards*	*Second Supplement to USP41–NF36*	Online	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Eszopiclone Related Compound A RS: [Note—This material may be

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								available in the free base or salt form.]
								6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81
								6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoic salt (1:1). $C_{17}H_{17}ClN_6O_4 \cdot C_7H_5ClO$ 561.38
								to:
								[Note—This

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								material may be available in the free base or salt form.] 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoate salt (1:1). $C_{17}H_{17}ClN_6O_4 \cdot C_7H_5ClO_2$ 561.38

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
FLUMAZENIL	IM PURITIES/*Limit of Flumazenil Related Compound C*	*USP41–NF36*	1775	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of *Standard solution B*: Change 0.12 ?g/mL to: 0.12 ?L/mL
SODIUM META BISULFITE	ASSAY/ *Proce dure/Analysis*	*USP41–NF36*	5573	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	In the Calculate statement: Change sodium metabisulfite ($Na_2S_2O_5$) to: sulfur dioxide (SO_2)
MONOSACCH ARIDE ANALYSIS	PROCEDURES /*Procedure 3: Enzymatic Hydrolysis and Analysis by RP-HPLC of DMB-labeled Sialic Acids*	*First Supplement to USP41–NF36*	Online	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 6 of *Analysis*: Change Convert the protein concentration from mg/mL to (1 ?M = 1 nmol/mL). to: Convert the protein concentration from mg/mL to ?M (1 ?M = 1

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								nmol/mL).
CARBIDOPA AND LEVODOPA TABLETS	ASSAY/*Procedure*/*Chromatographic system*	*USP41–NF36*	693	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Detector*: Change *Identification B*, to: *Identification A*,
ERYTHRITOL	IMPURITIES/*Related Compounds*/*Analysis*	*USP41–NF36*	5335	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2: Change *Samples*: *Standard solution* and *Sample solution* to: *Samples*: *Standard solution A* and *Sample solution* AND In the variable definition list: Change r_S = peak response of erythritol from the *Standard solution* C_S = concentration of USP Erythritol RS in the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution (mg/mL) to: r_S = peak response of erythritol from *Standard solution A* C_S = concentration of USP Erythritol RS in *Standard solution A* (mg/mL)
EVALUATION OF PLASTIC PACKAGING SYSTEMS AND THEIR MATERIALS OF CONSTRUCTION WITH RESPECT TO THEIR USER SAFETY IMPACT	APPLICABILITY AND APPLICATION OF <661.1>	*USP41–NF36*	7902	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 3 of *Application*/*4*.: Change proscribed to: prescribed AND Line 3 of *Description of Polymers Contained in <661.1 >*/ *Polyethylenes*: Change Low-density polypropylene

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(LDPE) to: Low-density polyethylene (LDPE) AND Line 6 of *Description of Polymers Contained in <661.1 >/ Polypropylene*: Change 0.3% polypropylene to: 0.3%. Polypropylene AND Line 3 of *Description of Polymers Contained in <661.1 >/Polyethylene Terephthalate and Polyethylene Terephthalate G*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ESZOPICLONE TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards*	*Second Supplement to USP41–NF36*	Online	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	1,4-cyclohexaemimethanol to: 1,4-cyclohexanedimethanol Line 2 of USP Eszopiclone Related Compound A RS: [Note—This material may be available in the free base or salt form.] 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5*H*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-pyr rolo[3,4 -*b*]pyrazin-5-yl 4 -methylpiperazi ne-1-carboxylat e 4-oxide, 3-chlorobenzoic salt (1:1). $C_{17}H_{17}ClN_6O_4$ · C_7H_5ClO 561.38 to: [Note – This material may be available in the free base or salt form.] 6-(5-Chloropyrid in-2-yl)-7-oxo-6, 7-di hydro-5*H* -pyr rolo[3,4 -*b*]pyrazin-5-yl 4 -methylpiperazi ne-1-carboxylat e 4-oxide. $C_{17}H_{17}ClN_6O_4$ 404.81 6-(5-Chloropyrid in-2-yl)-7-oxo-6, 7-di

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydro-5*H*-pyrrolo[3,4-*b*]pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide, 3-chlorobenzoate salt (1:1). $C_{17}H_{17}ClN_6O_4 \cdot C_7H_5ClO_2$ 561.38
LAMIVUDINE ORAL SOLUTION	ASSAY/*Procedure/Chromatographic system*	*USP41–NF36*	2328	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Flow rate*: Change 1 mL/mL to: 1 mL/min
COMPRESSIBLE SUGAR	IMPURITIES/*Limit of Calcium*	*USP41–NF36*	5631	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1: Delete Proceed as directed in *Identification Tests—General <191>*, *Calcium*.
ZIPRASIDONE HYDROCHLORIDE	IM PURITIES/*Organic Impurities/Analysis*	*Second Supplement to USP41–NF36*	8993	25-May-2018	1-Jun-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	In the second Calculate statement: Change chloroindolinone and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								ziprasidone related compound F to: chloroindolinone, ziprasidone related compound F, and any individual unspecified impurity AND In the second variable definition list: Change *F* = relative response factor for chloroindolinone or ziprasidone related compound F from *Table 3* to: *F* = relative response factor for chloroindolinone or ziprasidone

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								related compound F or any individual unspecified impurity from *Table 3*
DESLORATADINE TABLETS	IMPURITIES	*USP41–NF36*	1178	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	*Organic Impurities*: Add Protect all solutions containing desloratadine from light.
ISOSORBIDE DINITRATE SUBLINGUAL TABLETS	*Identification*	*USP41–NF36*	2272	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1: Change Tablets respond to the *Identification* test under *Isosorbide Dinitrate Tablets*. to: Transfer a suitable quantity of finely powdered Tablets to a glass-stoppered centrifuge tube. Add 10 mL of sodium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydroxide solution (1 in 250), shake to wet the powder, then add 15 mL of solvent hexane, and again shake. Centrifuge the mixture, and transfer the upper phase to a beaker. Evaporate the solvent, and dry the residue in vacuum over anhydrous calcium chloride at room temperature for 16 hours: the IR absorption spectrum of a suitable solution in chloroform of the residue so obtained exhibits maxima only at the same

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								wavelengths as that of a similar preparation from the residue obtained from USP Diluted Isosorbide Dinitrate RS.
HYDROGENATED VEGETABLE OIL	DEFINITION	*USP41–NF36*	5649	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2: Change The melting range, heavy metals limit, iodine value, and saponification value differ, to: The melting range, iodine value, and saponification value differ,
PEMETREXED FOR INJECTION	ASSAY/ *Procedure/Analysis*	*First Supplement to USP41–NF36*	Online	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 8 of the variable definition list: Change M_{r2} = molecular weight of pemetrexed disodium (anhydrous),

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								473.37 to: M_{r2} = molecular weight of pemetrexed disodium (anhydrous), 471.38
DRUG RELEASE	GENERAL DRUG RELEASE STANDARDS	*USP41–NF36*	6471	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Figure 5: Change O to: Ø
ISOSORBIDE DINITRATE CHEWABLE TABLETS	*Identification*	*USP41–NF36*	2270	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1: Change Chewable Tablets respond to the *Identification* test under *Isosorbide Dinitrate Tablets*. to: Transfer a suitable quantity of finely powdered Tablets to a glass-stoppered centrifuge tube. Add 10 mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sodium hydroxide solution (1 in 250), shake to wet the powder, then add 15 mL of solvent hexane, and again shake. Centrifuge the mixture, and transfer the upper phase to a beaker. Evaporate the solvent, and dry the residue in vacuum over anhydrous calcium chloride at room temperature for 16 hours: the IR absorption spectrum of a suitable solution in chloroform of the residue so obtained exhibits maxima only at the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								same wavelengths as that of a similar preparation from the residue obtained from USP Diluted Isosorbide Dinitrate RS.
ETHYL ACETATE	IM PUR ITIES/ *Chromatographic Purity*	*USP41–NF36*	5336	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 3 of *Acceptance criteria*: Change Ethyl isobutyl ether: to: 1-Ethoxy-2-methylpropane:
STATISTICAL TOOLS FOR PROCEDURE VALIDATION	3. ACCURACY AND PRECISION	*USP41–NF36*	7622	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 4 of paragraph 3 of *3.2 Combined Validation of Accuracy and Precision*: Change validate evaluate to: validate AND Variable definition in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								paragraph 6 of *3.2 Combined Validation of Accuracy and Precision*: Change $Z^2(1 + P)/2$ = standard normal to: $Z^2(1 + P)/2$ = the square of the standard normal
ARGATROBAN	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP41–NF36*	346	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 2 of USP Argatroban Related Compound B RS: Change Ethyl (2*R*,4*R*)-1-[N^8-nitro-L-arginyl]-4-methylpiperidine-2-carboxylate hydrochloride. $C_{15}H_{28}N_6O_5$? HCl 408.88 to: Ethyl (4*R*)-1-[N^8-nitro-L-arginyl]-4-methylpiperidine-2-

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								carboxylate dihydrochloride. $C_{15}H_{28}N_6O_5$? 2HCl 445.34
DIDANOSINE FOR ORAL SOLUTION	ASSAY/ *Procedure/ Chromatographic system*	*USP41–NF36*	1275	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Guard column*: Change 20-cm; to: 20-mm;
ISOSORBIDE DINITRATE SUBLINGUAL TABLETS	*Assay*	*USP41–NF36*	2272	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Change *Buffer solution*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution* —Dissolve 15.4

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about 4.7. *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). *Internal*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								standard solution—Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard preparation—Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Buffer solution (1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter. AND Add *Chromatographic system* (see

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Chromatography <621>)—The liquid chromatograph is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								replicate injections determined from the peak response ratios is not more than 2%. [Note—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
REAGENTS	S OL UTION S/*Volumetric Solutions*	*USP41–NF36*	5769	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *0.1 N Potassium Hydroxide VS*: Change Transfer 100 mL of potassium hydroxide to a 1000-mL volumetric flask. to: Transfer 100 mL of *1 N Potassium Hydroxide VS* to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								a 1000-mL volumetric flask.
REPOSITORY CORTICOTROPIN INJECTIONS	ADDITIONAL REQUIREMENTS	*USP41–NF36*	1097	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	In *USP Reference Standards <11>*: Add USP Ascorbic Acid RS
ISOSORBIDE DINITRATE CHEWABLE TABLETS	*Assay*	*USP41–NF36*	2270	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Change *Buffer solution, Mobile phase, Internal standard solution, Standard preparation,* and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*. to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about 4.7. *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>.) *Internal standard solution*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								—Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to settle, filter, and store the filtrate in an airtight container. *Standard prep*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								aration—Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to room temperature, dilute with *Mobile phase* to volume, and mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter. AND Add *Chromatographic system* (see *Chromatography* <621>)—The

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								liquid chromatograph is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than 2.0; and the relative standard deviation for replicate injections

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								determined from the peak response ratios is not more than 2%. [Note—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under *Diluted Isosorbide Dinitrate*. to: Separately inject equal

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
REAGENTS	REAGENT SPECIFICATIONS	*USP41–NF36*	5680	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Carbon Disulfide, CS*: Change Carbon Disulfide, CS to: Carbon Disulfide, CS_2
COLCHICINE	IM PURITIES/*Limit of Ethyl Acetate*/*System suitability*/*Suitability requirements*	*First Supplement to USP41–NF36*	8314	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Delete *Tailing factor*: NMT 2.0 for the menthol peak
ARGATROBAN	IM	*USP41–NF36*	346	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second*	Footnote b of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	PUR ITIES/*Organic Impurities*						*Supplement to USP41–NF36*	*Table 2*: Change Ethyl (2*R*,4*R*)-1-[N^8-nitro-L-arginyl]-4-methylpiperidine-2-carboxylate hydrochloride. to: Ethyl (4*R*)-1-[N^8-nitro-L-arginyl]-4-methylpiperidine-2-carboxylate.
ISOSORBIDE DINITRATE TABLETS	*Assay*	*USP41–NF36*	2270	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Change *Buffer solution*, *Mobile phase*, *Internal standard solution*, *Standard preparation*, and *Chromatographic system*—Prepare as directed in the *Assay* under *Diluted Isosorbide Dinitrate*.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: *Buffer solution*—Dissolve 15.4 g of ammonium acetate in water, add 11.5 mL of glacial acetic acid, dilute with water to 1000 mL, and mix to obtain a solution having a pH of about 4.7. *Mobile phase*—Mix 350 mL of water, 100 mL of *Buffer solution*, and 550 mL of methanol. Cool to room temperature, dilute with water to 1000 mL, mix, degas, and filter. Make adjustments if necessary (see *System*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Suitability under *Chromatography* <621>). *Internal standard solution* —Transfer a quantity of diluted nitroglycerin to a suitable volumetric flask, add about 60% of the flask volume of methanol, sonicate for 5 minutes, and shake for 30 minutes. Dilute with methanol to volume to obtain a solution having a concentration of about 3 mg of nitroglycerin per mL, and mix. Allow any undissolved material to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								settle, filter, and store the filtrate in an airtight container. *Standard prep aration* —Transfer about 125 mg of recently mixed USP Diluted Isosorbide Dinitrate RS, accurately weighed, to a 50-mL volumetric flask, add about 30 mL of *Mobile phase*, shake for 30 minutes, dilute with *Mobile phase* to volume, and mix. Pipet 10 mL of the resulting solution into a 25-mL volumetric flask, and add 4.0 mL

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								of *Internal standard solution* and 4 mL of dilute *Buffer solution* (1 in 10). Cool to room temperature, dilute with *Mobile phase* to volume, and mix to obtain a solution having a known concentration of about 0.25 mg of isosorbide dinitrate per mL, based on the quantity of USP Diluted Isosorbide Dinitrate RS weighed and the labeled content of isosorbide dinitrate. Pass a portion of this solution through a 0.45-µm filter.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								AND Add *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 220-nm detector and a 4-mm × 25-cm column that contains packing L1. The flow rate is about 1 mL per minute. Chromatograph the *Standard preparation*, and record the peak responses as directed for *Procedure*: the resolution, *R*, between isosorbide dinitrate and nitroglycerin is not less than

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								2.0; and the relative standard deviation for replicate injections determined from the peak response ratios is not more than 2%. [Note—The relative retention times are about 0.75 for isosorbide dinitrate and 1.0 for nitroglycerin. The relative retention times for isosorbide mononitrates, if present, are about 0.38.] AND Line 1 of *Procedure*: Change Proceed as directed for *Procedure* in the *Assay* under

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Diluted Isosorbide Dinitrate. to: Separately inject equal volumes (about 20 µL) of the *Standard preparation* and the *Assay preparation* into the chromatograph, record the chromatograms, and measure the responses for the major peaks.
ZONISAMIDE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>*	*USP41–NF36*	4410	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of *Apparatus 2*: Change 75 rpm, with sinkers (see *Dissolution* <711>, *Figure 2a*) to: 75 rpm. Use suitable sinkers,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								if necessary.
REAGENTS/INDICATORS AND SOLUTIONS	SOLUTIONS/*Volumetric Solutions*/*0.01 M Sodium Thiosulfate VS*	*USP41–NF36*	5772	27-Apr-2018	1-May-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	In the equation in *Standardization*: Change N = mg $K_2Cr_2O_7$/49.04 x mL $Na_2S_2O_3$ to: M = mg $K_2Cr_2O_7$/49.04 x mL $Na_2S_2O_3$
PLASTIC MATERIALS OF CONSTRUCTION	TEST METHODS/*Tin in Non-Tin-Stabilized Materials*	*USP41–NF36*	6403	30-Mar-2018	1-Apr-2018	*USP42–NF37*	*USP42–NF37*	Line 3 of *Sample solution*: Change If the solution is not colorless, add the sodium sulfate to: If the solution is not colorless, add the sodium sulfite
PERINDOPRIL ERBUMINE	IMPURITIES/*Limit of Perindopril Related Compound I*/*System*	*USP40–NF35*	5644	30-Mar-2018	1-Apr-2018	*USP42–NF37*	*USP42–NF37*	Line 3: Add [Note—The relative retention times for perindopril and perindopril

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	suitability							related compound I are 1.0 and 1.6, respectively.]
SALMETEROL INHALATION POWDER	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*USP40–NF35*	6096	30-Mar-2018	1-Apr-2018	*USP42–NF37*	*USP42–NF37*	Line 2 of USP Salmeterol Related Compound H RS: Change 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid. $C_{36}H_{43}NO_6$ 585.73 to: 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid, monohydrate. $C_{36}H_{43}NO_6 \cdot H_2O$ 603.76
FLUTICASONE PROPIONATE	ADDITIONAL REQUIREMENT	*USP40–NF35*	4309	30-Mar-2018	1-Apr-2018	*USP42–NF37*	*USP42–NF37*	Line 2 of USP Salmeterol

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AND SALMETEROL INHALATION POWDER	S/*USP Reference Standards <11>*							Related Compound H RS: Change 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid. $C_{36}H_{43}NO_6$ 585.73 to: 1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid, monohydrate. $C_{36}H_{43}NO_6 \cdot H_2O$ 603.76
PAROXETINE HYDROCHLORIDE	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*First Supplement to USP40–NF35*	Online	23-Feb-2018	1-Mar-2018	*USP42–NF37*	*Second Supplement to USP41–NF36*	Line 1 of USP Paroxetine Related Compound F RS: Change *trans* (?)-1-Methyl-3-[1,3-benzodioxol

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								-5-yloxy)methyl]-4-(fluorophenyl)piperidine. to: (3*S*,4*R*)-3-[(Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methylpiperidine.

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 7
- Page 8
- Page 9
- Page 10
- Page 11
- Page 12
- Page 13
- Page 14
- Page 15
- …
- Next page Next ›
- Last page Last »